Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Intangibles (2022 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Intangibles for 4 consecutive years, with $131.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Intangibles fell 15.96% year-over-year to $131.7 million, compared with a TTM value of $131.7 million through Dec 2025, down 15.96%, and an annual FY2025 reading of $131.7 million, down 15.96% over the prior year.
  • Intangibles was $131.7 million for Q4 2025 at Catalyst Pharmaceuticals, down from $227.7 million in the prior quarter.
  • Across five years, Intangibles topped out at $227.7 million in Q4 2023 and bottomed at $32.5 million in Q4 2022.
  • Average Intangibles over 4 years is $169.4 million, with a median of $175.5 million recorded in 2023.
  • The sharpest move saw Intangibles surged 601.28% in 2023, then plummeted 31.2% in 2024.
  • Year by year, Intangibles stood at $32.5 million in 2022, then soared by 601.28% to $227.7 million in 2023, then plummeted by 31.2% to $156.7 million in 2024, then fell by 15.96% to $131.7 million in 2025.
  • Business Quant data shows Intangibles for CPRX at $131.7 million in Q4 2025, $227.7 million in Q3 2025, and $227.7 million in Q2 2025.